How NIST’s Biofoundary Automates Biology

How NIST’s Biofoundary Automates Biology

Engineering biological systems to solve problems is becoming almost commonplace. Ideas range from finding environmentally sustainable ways to mimic natural resources to building new kinds of medical treatments for deadly diseases. The enormous promise of such work is rapidly intercepting with actual results.  When physicist David Ross thinks of these things, he thinks a lot … Read more

Immunoinformatics Is The Exhaust From Genome Sequencing That Is Waiting To Be Mined

Immunoinformatics Is The Exhaust From Genome Sequencing That Is Waiting To Be Mined

One can think of the rapid growth of genome sequencing as producing a special kind of exhaust in the form immunologically relevant data that has accumulated in large quantities in databases around the world. Those databases can be mined. Immunoinformatics is emerging as an important tool at the intersection of experimental immunology and various computational … Read more

Team Builds the First Xenobot

Team Builds the First Xenobot

A team of scientists at University of Vermont has repurposed living cells—scraped from frog embryos—and assembled them into entirely new life-forms. These millimeter-wide “xenobots” can move toward a target, perhaps pick up a payload (like a medicine that needs to be carried to a specific place inside a patient)—and heal themselves after being cut. “These … Read more

FDA Approves First PARP Inhibitor For Treatment Of Pancreatic Cancer

FDA Approves First PARP Inhibitor For Treatment Of Pancreatic Cancer

In December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, according to AstraZeneca and Merck. The agent is now the only PARP inhibitor approved for … Read more